कंपनी का अवलोकन
Traws Pharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing small-molecule oral product candidates specifically targeting respiratory viral diseases and cancer. The company functions within the healthcare sector and the biotechnology industry, focusing on creating investigational novel therapies for influenza and COVID-19 that address treatment resistance issues. In terms of scale, Traws Pharma, Inc. maintains a market capitalization of $12.47M, generated annual revenue of $2.85M, and employs a workforce of 6 individuals. These financial figures indicate that the company is a micro-cap entity with a very small operational footprint, suggesting that it is in an early development phase where capital allocation is heavily concentrated in research and product candidate advancement rather than widespread commercial expansion.
वित्तीय स्वास्थ्य
The company reported a total revenue of $2.85M over the trailing twelve months, yet it recorded a net income of -$9,156,000 and an EBITDA of -$15,766,000, highlighting a significant divergence between top-line generation and profitability. This substantial gap between revenue and net income reveals a cost structure characterized by high operational expenses typical of clinical-stage biotechnology firms, where costs are incurred primarily for drug development and clinical trials before products reach market. The company's free cash flow stands at -$11,849,625, which indicates a current lack of financial flexibility as it burns through cash reserves to fund its operations and development pipeline. Analyzing the margins, the company holds a gross margin of 100.0%, reflecting the nature of selling intangible intellectual property or early-stage products without significant cost of goods sold, while the operating margin is -554.6% and profit margin is 0.0%, signaling that operating expenses far exceed gross revenue. Regarding liquidity, the firm holds $6.42M in cash against $0 in debt, creating a situation where the balance sheet is conservative in terms of leverage but strained by cash consumption. The debt-to-equity ratio is N/A due to the absence of debt, and the current ratio of 1.22 suggests the company possesses sufficient short-term assets to cover its current liabilities. Furthermore, the return on equity is -1059.6% and the return on assets is -92.3%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns while the company seeks to develop its therapeutic candidates.
मूल्यांकन आकलन
The valuation metrics present a challenging picture given the company's lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -0.36. The difference between a non-existent trailing P/E and a negative forward P/E implies that traditional earnings-based valuation models are not applicable, as the market prices the stock based on asset value or development potential rather than current earnings power. The price-to-book ratio is 2.45, which indicates that the market is valuing the company at a significant premium over its tangible book value, likely driven by the perceived potential of its pipeline of novel therapies for influenza and COVID-19. Additional alternative valuation metrics include a price-to-sales ratio of 4.38 and an EV/EBITDA of -0.38, suggesting that investors are willing to pay a high multiple per dollar of revenue despite the company's negative earnings and cash flow. Regarding trading range, the 52-week high is $3.27 and the 52-week low is $0.97, placing the current price context within a highly volatile band where the stock has demonstrated substantial fluctuation relative to its historical trading levels. The beta value is 1.62, which means the stock's price volatility is significantly higher than the broader market, moving 62% more than the market average during periods of price swings.
Growth & Income
The company's revenue growth year-over-year is N/A, as there is no comparable prior year data available in the provided facts to calculate a growth rate, and earnings growth year-over-year is also N/A due to the lack of profitability. Since the company has not achieved positive earnings, it is impossible to determine if earnings are growing faster than revenue in a traditional sense, but the negative growth metrics reflect the early-stage nature of the business where losses are expected. For non-dividend payers, Traws Pharma, Inc. does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies the company reinvests all available resources and any generated income back into its research and development efforts rather than paying shareholders. Consequently, the overall growth and income profile is defined by a complete reliance on external capital or cash reserves to fuel expansion, with no current income generation for investors and no dividend payout to provide regular returns.